MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
5.76
+0.10 (1.77%)
At close: Feb 21, 2025, 4:00 PM
5.80
+0.04 (0.70%)
After-hours: Feb 21, 2025, 7:58 PM EST
MannKind Employees
As of December 31, 2023, MannKind had 414 total employees, including 411 full-time and 3 part-time employees. The number of employees increased by 19 or 4.81% compared to the previous year.
Employees
414
Change (1Y)
19
Growth (1Y)
4.81%
Revenue / Employee
$645,411
Profits / Employee
$52,094
Market Cap
1.59B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
MNKD News
- 2 days ago - MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025 - GlobeNewsWire
- 19 days ago - MoneyShow's Best Investment Ideas For 2025: Part 8 - Seeking Alpha
- 6 weeks ago - MannKind Expands Executive Leadership Team - GlobeNewsWire
- 2 months ago - MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets - Seeking Alpha
- 2 months ago - MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®) - GlobeNewsWire
- 2 months ago - CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India - GlobeNewsWire
- 3 months ago - MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 3 months ago - MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire